- CARRIE study did not meet primary or secondary endpoints -
- Company ceases development of MM-141 -
- Focus remains on advancing Merrimack's promising clinical and preclinical pipeline, with two additional clinical study readouts anticipated in 2H 2018 -
PR Newswire
CAMBRIDGE, Mass., June 25, 2018